Show simple item record

dc.contributor.author Csörgőné Szabó, Szilvia
dc.contributor.author Xu Y,
dc.contributor.author Romero R,
dc.contributor.author Fule T,
dc.contributor.author Karaszi K,
dc.contributor.author Krenács, Tibor
dc.contributor.author Papp, Zoltán
dc.contributor.author Kovalszky, Ilona
dc.contributor.author Than, Nándor Gábor
dc.date.accessioned 2015-02-16T11:11:51Z
dc.date.available 2015-02-16T11:11:51Z
dc.date.issued 2013
dc.identifier 84884146687
dc.identifier.citation pagination=445-458; journalVolume=463; journalIssueNumber=3; journalTitle=VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY;
dc.identifier.uri http://repo.lib.semmelweis.hu//handle/123456789/1408
dc.identifier.uri doi:10.1007/s00428-013-1426-0
dc.description.abstract Preeclampsia is characterized by maternal systemic anti-angiogenic and pro-inflammatory states. Syndecan-1 is a cell surface proteoglycan expressed by the syncytiotrophoblast, which plays an important role in angiogenesis and resolution of inflammation. Our aim was to examine placental syndecan-1 expression in preeclampsia with or without hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Placentas were obtained from women in the following groups: (1) late-onset preeclampsia (n = 8); (2) early-onset preeclampsia without (n = 7) and (3) with HELLP syndrome (n = 8); (4) preterm controls (n = 5); and (5) term controls (n = 9). Tissue microarrays (TMAs) were constructed from paraffin-embedded placentas. TMA slides were immunostained for syndecan-1 and evaluated using microscopy, virtual microscopy, and semi-automated image analysis. Maternal sera from patients with preeclampsia (n = 49) and controls (n = 32) were immunoassayed for syndecan-1. BeWo cells were treated with Forskolin or Latrunculin B or kept in ischemic conditions. SDC1 expression and syndecan-1 production were investigated with qRT-PCR, confocal microscopy, and immunoassays. Syndecan-1 was localized to the syncytiotrophoblast apical membrane in normal placentas. Syndecan-1 immunoscores were higher in late-onset preeclampsia (p = 0.0001) and early-onset preeclampsia with or without HELLP syndrome (p = 0.02 for both) than in controls. Maternal serum syndecan-1 concentration was lower in preeclampsia (median, 673 ng/ml; interquartile range, 459-1,161 ng/ml) than in controls (1,158 ng/ml; 622-1,480 ng/ml). SDC1 expression and syndecan-1 immunostainings in BeWo cells and syndecan-1 concentrations in supernatants increased during cell differentiation. Disruption of the actin cytoskeleton with Latrunculin B decreased syndecan-1 release, while ischemic conditions increased it. Syncytiotrophoblastic syndecan-1 expression depends on the differentiation of villous trophoblasts, and trophoblastic syndecan-1 release is decreased in preeclampsia and HELLP syndrome. This phenomenon may be related to the disturbed syncytiotrophoblastic cortical actin cytoskeleton and associated with maternal anti-angiogenic and pro-inflammatory states in these syndromes. © 2013 Springer-Verlag Berlin Heidelberg (outside the USA).
dc.relation.ispartof urn:issn:0945-6317
dc.title Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome
dc.type Journal Article
dc.date.updated 2015-02-16T11:11:17Z
dc.language.rfc3066 en
dc.identifier.mtmt 2376774
dc.identifier.wos 000323904700010
dc.identifier.pubmed 23807541
dc.contributor.department SE/AOK/I/I. Sz. Patológiai és Kísérleti Rákkutató Intézet
dc.contributor.department SE/ETK/AEI/Morfológiai és Fiziológiai Tanszék
dc.contributor.institution Semmelweis Egyetem


Files in this item

This file is available only from Semmelweis network

View/Open

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account